- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02937116
First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors
An Open-Label, Multicenter Study of IBI308 in Subjects With Selected Advanced Solid Tumors
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- The fifth medical center of the PLA general hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status grade 0 or 1
- Adequate bone marrow, liver, and renal function defined as: 1) Absolute neutrophil count >= 1.5* 10^9 cells/litre (L); 2) Platelets >=100 x 10^9 cells/L; 3) Hemoglobin >= 9 gram/deciliter (g/dL); 4) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 * upper limit of normal (ULN) for participants without hepatic cell cancer and hepatic metastasis, ALT and AST <= 5 * ULN for participants with hepatic cell cancer or hepatic metastasis; 5) Total bilirubin (TBIL) < 1.5 * ULN for participants without hepatic cell cancer, hepatic metastasis and confirmed/suspicious Gilbert syndrome, TBIL < 3 * ULN for participants with hepatic cell cancer, hepatic metastasis or confirmed/suspicious Gilbert syndrome; 6) Creatinine determined by serum creatinine levels <=1.5 * ULN or a calculated creatinine clearance of >= 50 mL/min/1.73 m^2; 7) urine protein -~+, 24 hour urine < 1 gram for participants with urine protein ++ or above; 8) activated partial thromboplastin time and international normalized ratio <= 1.5 * ULN; 9) thyroid stimulating hormone and free thyroxine 4 within normal range
Tumor type
- Phase 1a: advanced solid tumors after failure of standard therapy
- Phase 1b Cohort A: cytologically or histologically confirmed advanced melanoma
- Phase 1b Cohort B: cytologically or histologically confirmed advanced malignancies of the digestive system after failure of at least 1 line of standard therapy
- Phase 1b Cohort C: cytologically or histologically confirmed advanced NSCLC without known epithelial growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement after failure of 1st line standard therapy
- Phase 1b Cohort D: treatment naive cytologically or histologically confirmed inoperable locally advanced (stage IIIB) or advanced (stage IV) nsNSCLC without known EGFR mutation and ALK rearrangement, participants with disease recurrence or progression within 6 months after completion of prior platinum doublet-based chemotherapy regimen as neoadjuvant or adjuvant therapy are not eligible
- Phase 1b Cohort E: Cytologically or histologically confirmed, treatment naïve locally advanced, recurrent or metastatic squamous NSCLC without known EGFR mutation and ALK rearrangement. Participants with Stage IIIB NSCLC who progressed within 6 months after completion of platinum-based chemotherapy are not eligible.
- Phase 1b Cohort F: Histologically confirmed locally advanced, recurrent or metastatic gastric or esophagogastric junction adenocarcinoma without known HER2 amplification.
- Phase 1b Cohort G: Cytologically or histologically confirmed, treatment naïve locally advanced, recurrent or metastatic high grade(G3) neuroendocrine tumor with Ki-67>20%.
- Phase 1b Cohort H: Cytologically or histologically confirmed advanced high grade(G3) neuroendocrine tumor with Ki-67>20% after failure of first line standard therapy. Participants progressed within 6 months after completion of adjuvant or neoadjuvant chemotherapy are eligible.
- At least 1 measurable site of disease per RECIST v1.1
Exclusion Criteria:
- Prior treatment of any antibody of PD-1 or PD-L1
Prior treatment of ipilimumab, unless all the following requirements are met:
- Full resolution of ipilimumab related adverse effects (including immune related adverse effects) and no treatment for these adverse events (AEs) for at least 4 weeks prior to the time of enrollment
- Minimum of 12 weeks from the first dose of ipilimumab and >6 weeks from the last dose
- No history of severe immune related adverse effects from ipilimumab (CTCAE Grade 4; CTCAE Grade 3 requiring treatment >4 weeks)
- Unequivocal PD following a dose of ipilimumab
- HIV infection
- Active HBV or HCV infection
Uncontrolled complication including but not limited to :
- Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias or congestive heart failure
- History of stroke, myocardial infarction or intracranial hemorrhage within 6 months prior to the enrolment
- History or risk of autoimmune disease
- Known interstitial lung disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase 1a
Participants will receive IBI308 1mg/kg, 3mg/kg or 10mg/kg intravenous every 2 weeks, or 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity. Drug: IBI308 |
|
Experimental: Phase 1b Cohort A
Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308 |
|
Experimental: Phase 1b Cohort B
Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308 |
|
Experimental: Phase 1b Cohort C
Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308 |
|
Experimental: Phase 1b Cohort D
Participants will receive IBI308 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308/Cisplatinum/Pemetrexed |
|
Experimental: Phase 1b Cohort E
Participants will receive IBI308 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308\gemcitabine\cisplatin |
|
Experimental: Phase 1b Cohort F
Participants will receive IBI308 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308\oxaliplatin\capecitabine |
|
Experimental: Phase 1b Cohort G
Participants will receive IBI308 200mg in combination with cisplatin 75mg/m2 intravenously and etoposide 100mg/m2 intravenously day 1 to 3 of every 3 weeks for upto 6 cycles. Those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308\etoposide\cisplatin |
|
Experimental: Phase 1b Cohort H
Participants will receive IBI308 200mg in combination with irinotecan 125mg/m2 intravenously day 1and 8 and 5-FU 1000mg/m2 intravenously day 1 to 3 of every 3 weeks for upto 6 cycles.Those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308\irinotecan\5-FU |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Experiencing Dose-limiting Toxicities (DLTs)
Time Frame: Up to 28 days in Cycle 1
|
Up to 28 days in Cycle 1
|
|
Number of All Study Participants Who Demonstrate a Tumor Response
Time Frame: Through out the study (up to 2 years)
|
Through out the study (up to 2 years)
|
|
Objective Response Rate (ORR) According to RECIST 1.1 as Assessed by Independent Review Committee by Investigator
Time Frame: Through out the study (up to 2 years)
|
ORR was defined as the percentage of participants in the analysis population who had achieved BOR of CR or PR according to RECIST 1.1.
|
Through out the study (up to 2 years)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PFS According to RECIST 1.1 as Assessed by Investigator
Time Frame: Through out the study (up to 2 years)
|
Through out the study (up to 2 years)
|
DOR According to RECIST 1.1 as Assessed by Investigator
Time Frame: Through out the study (up to 2 years)
|
Through out the study (up to 2 years)
|
TTR According to RECIST 1.1 as Assessed by Investigator
Time Frame: Through out the study (up to 2 years)
|
Through out the study (up to 2 years)
|
OS for Participants
Time Frame: Through out the study
|
Through out the study
|
Area Under the Concentration-time Curve From Zero Time (Predose) to the Time of the Last Measurable Concentration (AUC0-t)
Time Frame: Cycle 1: pre-dose, post-dose at 0, 1, and 6 hours, and Days 2, 3, 8, 15, and 22, and 29
|
Cycle 1: pre-dose, post-dose at 0, 1, and 6 hours, and Days 2, 3, 8, 15, and 22, and 29
|
Maximum Concentration (Cmax) of Sintilimab in Solid Tumor Participants
Time Frame: Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29
|
Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29
|
Time to Maximum Concentration (Tmax) of Sintilimab in Solid Tumor Participants
Time Frame: Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29
|
Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29
|
The Half-life (t1/2) of IBI308 in Plasma After Single Dose Administration
Time Frame: Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29
|
Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29
|
Volume of Distribution of IBI308 in Plasma After Single Dose Administration
Time Frame: Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29
|
Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29
|
Clearance of IBI308 in Plasma After Single Dose Administration
Time Frame: Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29
|
Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Jiang H, Zheng Y, Qian J, Mao C, Xu X, Li N, Xiao C, Wang H, Teng L, Zhou H, Wang S, Zhu D, Peng B, Shen L, Xu N. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial. BMC Cancer. 2020 Aug 14;20(1):760. doi: 10.1186/s12885-020-07251-z.
- Jiang H, Zheng Y, Qian J, Mao C, Xu X, Li N, Xiao C, Wang H, Teng L, Zhou H, Wang S, Zhu D, Sun T, Yu Y, Guo W, Xu N. Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study. Cancer Immunol Immunother. 2021 Mar;70(3):857-868. doi: 10.1007/s00262-020-02738-x. Epub 2020 Oct 17.
- Wei J, Lu X, Liu Q, Fu Y, Liu S, Li L, Liu F, Fan X, Yang J, Yang Y, Zhao Y, Guan W, Liu B. Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial. Cancer Manag Res. 2022 Jun 17;14:2007-2015. doi: 10.2147/CMAR.S355687. eCollection 2022.
- Jia R, Li Y, Xu N, Jiang HP, Zhao CH, Liu RR, Shi Y, Zhang YY, Wang SY, Zhou H, Xu JM. Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms. Oncologist. 2022 Aug 5;27(8):e625-e632. doi: 10.1093/oncolo/oyac097.
- Jiang H, Li N, Wang H, Chen Z, Zheng Y, Qian J, Mao C, Xu X, Xiao C, Zhang X, Zhou H, Wang S, Chen W, Yin X, Sun J, Peng B, Teng L, Xu N. Assessment of TMB, PD-L1, and lymphocyte to monocyte ratio as predictive potential in a phase Ib study of sintilimab in patients with advanced solid tumors. Am J Cancer Res. 2021 Sep 15;11(9):4259-4276. eCollection 2021.
- Zhang J, Wu L, Liu J, Lin M. A metastatic intrahepatic cholangiocarcinoma treated with programmed cell death 1 inhibitor: a case report and literature review. Immunotherapy. 2020 Jun;12(8):555-561. doi: 10.2217/imt-2019-0100. Epub 2020 May 6.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Topoisomerase I Inhibitors
- Folic Acid Antagonists
- Gemcitabine
- Etoposide
- Cisplatin
- Capecitabine
- Oxaliplatin
- Irinotecan
- Pemetrexed
Other Study ID Numbers
- CIBI308A101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer, Solid Tumor
-
Albert Einstein College of MedicineTerminatedCancer | Solid Tumor | Metastatic Solid Tumor | Metastatic dMMR Solid CancerUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
Spago Nanomedical ABRecruitingSolid Tumor | Metastatic Cancer | Refractory Cancer | Locally Advanced Solid Tumor | Unresectable Solid Tumor | Recurrent Solid TumorAustralia
-
Invitae CorporationRecruitingCancer | Solid Tumor | Solid Tumor, AdultUnited States
-
Novartis PharmaceuticalsTerminatedCancer | Solid Tumor | Advanced Solid TumorJapan
-
Sairopa B.V.RecruitingMetastatic Solid Tumor | Solid Tumor, Adult | Refractory CancerUnited States, Moldova, Republic of
-
Daiichi Sankyo Co., Ltd.RecruitingSolid Tumor | Metastatic Solid Tumor | Advanced CancerJapan, United States, Canada
-
Panolos BioscienceRecruitingMetastatic Colorectal Cancer | Hepatocellular Carcinoma | Gastric Cancer | Solid Tumor | Advanced Solid Tumor | Solid Tumor, AdultKorea, Republic of
-
Imugene LimitedRecruitingSolid Tumor | Metastatic Cancer | Advanced Solid Tumor | Solid Tumor, Adult | Solid CarcinomaUnited States, Australia
-
Aadi Bioscience, Inc.RecruitingMalignant Solid Neoplasm | Neoplasms | Cancer | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Metastasis | Advanced Solid Tumor | Metastatic Solid Tumor | Advanced Cancer | Tumor | Malignant Neoplasm | Malignant Tumor | Tumors | Cancer Metastatic | Tumor, Solid | Malignant Solid Tumor | TSC | TSC1 | TSC2 | Metastatic NeoplasmKorea, Republic of, United States, Puerto Rico
Clinical Trials on IBI308
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedAdvanced/Metastatic Solid MalignanciesUnited States
-
Shanghai Ninth People's Hospital Affiliated to...UnknownPrecancerous Conditions | Oral Cavity Cancer | Mouth NeoplasmChina
-
Innovent Biologics (Suzhou) Co. Ltd.Active, not recruitingAdvanced Hepatocellular CarcinomaChina
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingAdvanced Biliary Tract CancerChina
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedAdvanced Solid TumorChina
-
Beijing Tsinghua Chang Gung HospitalUnknownHepatocellular Carcinoma | Portal Vein Tumor ThrombosisChina
-
Innovent Biologics (Suzhou) Co. Ltd.Completed
-
Harbin Medical UniversityInnovent Biologics (Suzhou) Co. Ltd.Not yet recruitingAdvanced Gastric/Gastroesophageal Junction Adenocarcinoma
-
Fujian Haixi Pharmaceuticals Co., Ltd.Recruiting
-
Sichuan Cancer Hospital and Research InstituteInnovent Biologics, Inc.UnknownNeoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-small-cell Lung Cancer